HealWELL AI Inc

HEALWELL’s Khure Health Provides Update Highlighting Significant Acceleration in User and Life Sciences Partner Adoption of Disease Detection AI Powered Co-Pilots and Strong Physician NPS Scores

      • In Q4-2024, HEALWELL’s subsidiary, Khure Health (“Khure”) helped physicians identify over 43,000 high-risk patients with its AI-Powered Physician Co-Pilots, across 8 clinical specialities harnessing 132 disease specific algorithms. This figure reflected a quarter over quarter sequential growth of 22% as compared to Q3-2024 and year-over-year growth of 500% as compared to Q4-2023.

      • HEALWELL has now on-boarded over 800 physicians that use its Expert-System AI-Powered Khure Physician Co-Pilots. These results include physicians that participated as part of WELL Health’s network through the ‘WAIDS’ or ‘WELL AI Decision Support’ Program, which is currently the fastest growing component of the HEALWELL-Khure network.

      • HEALWELL recently conducted a survey of the physicians that leverage the Khure powered co-pilots that resulted in an industry outperforming Net Promoter Score (NPS) of 84, with 82% of physicians confirming that they believed that the AI powered physician Co-Pilot technology helped improve patient care.

      • HEALWELL has executed 4 new Master Services Agreements (“MSA”) with new pharmaceutical partners in Q4-2024 relating to the Khure program; bringing the total number of MSAs with life sciences partners to 16, which includes 7 of the 10 largest pharmaceutical companies in the world.

      TORONTO, ON, February 24, 2025 – HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX:HWAIF), a healthcare artificial intelligence company focused on preventative care, is pleased to provide a corporate update highlighting its subsidiary, Khure Health Inc. (“Khure”) experiencing significant acceleration in user and life sciences partner adoption of its disease detection expert-system AI powered co-pilots (“Co-Pilots”). In Q4-2024, Khure’s Co-Pilots helped physicians identify over 43,000 high-risk patients across 8 clinical specialities, harnessing 132 disease specific algorithms. This figure reflected a quarter over quarter sequential growth of 22% as compared to Q3-2024 and year-over-year growth of 500% as compared to Q4-2023. Also, during Q4-2024, HEALWELL executed 4 new Master Services Agreements (“MSA“) with new large pharmaceutical partners relating to the Khure program; bringing the total number of MSAs with life sciences partners to 16, which includes 7 of the 10 largest pharmaceutical companies in the world.
       
      Dr. Alexander Dobranowski, CEO of HEALWELL, comments, “We are incredibly proud of the momentum our Co-Pilots are experiencing. In Q4 alone, our Khure technology identified 43,000 high risk patients. This made it easier for physicians to not only identify at risk patients but also confidently triage next steps efficiently. We now have 800 physicians using this technology and experienced 500% YoY growth and 22% QoQ growth in the number of patients identified alone. Our partnership with WELL Health is working extremely well as a substantial component of our growth is now coming from the WELL Health Network which includes WELL clinics as well as the WELLSTAR provider network.

      We’re also pleased to report that Khure has shown significant growth in terms of its commercialization efforts with pharma and life sciences companies as we’ve expanded our partnerships and signed new master services agreements that further integrate our disease detection algorithms into critical research and patient care workflows. At HEALWELL, we remain committed to harnessing the power of AI to drive earlier disease detection and improve patient outcomes.”
       
      Additionally, HEALWELL’s Khure recently conducted a survey of its physician users that resulted in an industry outperforming Net Promoter Score (NPS) of 84, with 82% of physicians confirming that they believed that the Co-Pilot technology helped improve patient care; thus highlighting the quality, clinical relevance and useability of Khure’s Clinical Decision Support (CDS) platform.

        HEALWELL has now on-boarded over 800 physicians that use its Khure Co-Pilots. The results above include physicians that participated as part of the WELL Health Technologies Corp. (“WELL”) clinical network, which includes the expanded WELLSTAR Technologies Corp. provider network, which offers the technology under the ‘WAIDS’ or ‘WELL AI Decision Support’ program which is currently the fastest growing component of Khure’s business. Physicians using WAIDS represented approximately 80% of physicians that were onboarded into Khure in Q4.

        Don Watts, President of Khure Health, further adds, “Physicians using our AI decision support platform consistently report high satisfaction, as reflected in our industry-leading Net Promoter Scores (NPS). They tell us that our platform is easy to use, saves them valuable time, and most importantly is helping them to improve patient care. By enabling physicians with advanced technology and supporting enhanced clinical decision-making, we’re helping providers focus on what matters most – delivering the best possible outcomes for their patients.”

         

        Dr. Alexander Dobranowski
        Chief Executive Officer
        HEALWELL AI Inc.

          About HEALWELL AI

          HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company’s road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit https://healwell.ai/.

          Forward Looking Statements

          Certain statements in this press release, constitute “forward-looking information” and “forward looking statements” (collectively, “forward looking statements”) within the meaning of applicable Canadian securities laws, including statements about the potential for HEALWELL and its partners to continually leverage advancements in expert AI technologies to develop new products and services or enhance existing ones to serve its existing (and future) customer base, and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as “possibility”, “opportunity”, “pending”, “proposition”, “continue to”, “improve” or variations of such words and phrases or statements that certain future conditions, actions, events or results “will”, “may”, “could”, “would”, “should”, “might” or “can” be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL’s control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: HEALWELL’s ability to maintain and leverage is relationships with its commercial partners; the continued adoption of the software, tools and solutions created by HEALWELL; that HEALWELL will be successful in identifying, executing and integrating new acquisitions, investments and/or partnerships, the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL’s ability to comply with applicable laws and regulations; HEALWELL’s continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL’s business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.

          Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled “Risk Factors” in HEALWELL’s most recent annual information form dated April 1, 2024, which is available under HEALWELL’s SEDAR+ profile at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.

           

          For more information:

          Pardeep S. Sangha  
          Investor Relations, HEALWELL AI Inc. 
          Phone: 604-572-6392  
          ir@healwell.ai 

          Khure Health

          Khure Health is a wholly owned subsidiary of HEALWELL AI. Khure is an AI health technology company whose precision medicine platform harnesses clinical data, enabling physicians to rapidly screen and identify patients with rare diseases and facilitate more personalized treatment.

          Khure is actively working with and/or has rare and specialty disease programs in development with 6 of the top 10 pharma companies and international disease associations.
          Visit Website →

          This will close in 0 seconds

          Pentavere

          HEALWELL AI is a majority shareholder of Pentavere Research Group, a globally recognized and award-winning AI digital health company that has built a best-in-class AI engine to identify patients that are eligible for approved medications or interventions, to improve outcomes for patients and help drive therapy growth and penetration. Over the past several years, Pentavere has published an impressive array of literature in high-impact, peer-reviewed medical journals, totaling more than 30 manuscripts, which serve as a testament to Pentavere’s capabilities and adds significant credibility to their technology.
          Visit Website →

          This will close in 0 seconds

          Intrahealth

          Intrahealth is a pioneering force in healthcare technology, specializing in the development and implementation of state-of-the-art EMR solutions. With a relentless commitment to advancing patient care, Intrahealth empowers healthcare providers, institutions, and governments with innovative digital tools designed to enhance healthcare delivery and improve patient outcomes.
          Visit Website →

          This will close in 0 seconds

          VeroSource Solutions

          VeroSource Solutions is a digital health company established in 2014 to empower people and unlock the potential in Canadian healthcare. Its team of professionals has extensive experience in the full lifecycle of healthcare IT solutions and offers healthcare providers the technology and support needed to go digital. VeroSource’s cloud-first multi-channel software securely connects people, data and systems to drive digital healthcare transformation. Founded in Fredericton, NB, VeroSource has grown to include team members across Ontario and Atlantic Canadian.
          Visit Website →

          This will close in 0 seconds

          BioPharma Services

          BioPharma Services is a leading contract research organization (CRO) based in Toronto, Canada, specializing in Phase 1 and Phase 2a clinical trials. With a focus on scientific integrity, operational excellence, and adaptive processes tailored to each client’s needs, BioPharma Services has established a reputation for delivering high-quality results in the pharmaceutical and biotech industries. BioPharma’s comprehensive services also include Bioanalysis at their GLP Certified Laboratory, Scientific and Regulatory Affairs, Biostatistics and Safety Data Analysis (CDISC), Data Management and Medical Writing.
          Visit Website →

          This will close in 0 seconds

          PolyClinic

          HEALWELL AI Polyclinic provides onsite integrated health services including primary care, specialist care, lab services, and an in-house clinical research organization. With integrated systems and data-driven tools, HEALWELL AI Polyclinic plans to unlock meaningful insights from consistent, high-quality, structured clinical information from over 50 primary care physicians and specialists, labs, and clinical trials.
          Visit Website →

          This will close in 0 seconds

          Doctorly

          Founded in 2018, doctorly is a European based digital health-tech startup with a company mission of 'enabling people to live healthier lives'. With an initial focus on Europe’s largest market, Germany, doctorly has built a brand new, fully regulated practice management software to redefine how medical practices work. As an all-in-one solution, doctorly provides a fully centralised, cloud powered, GDPR compliant, medical practice operating system that dramatically reduces the time and effort doctors and medical assistants spend on day-to-day administrative tasks. doctorly is financially backed by some of the world’s most renowned venture capital firms. To learn more about doctorly please visit: www.doctorly.de

          Read the original press release here.
          Visit Website →

          This will close in 0 seconds

          xAI

          xAI is a company working on building artificial intelligence to accelerate human scientific discovery. They're guided by their mission to advance our collective understanding of the universe. The team is led by Elon Musk, CEO of Tesla and SpaceX. Collectively their team has contributed some of the most widely used methods in the field, in particular the Adam optimizer, Batch Normalization, Layer Normalization, and the discovery of adversarial examples. They further introduced innovative techniques and analyses such as Transformer-XL, Autoformalization, the Memorizing Transformer, Batch Size Scaling, μTransfer, and SimCLR. They have worked on and led the development of some of the largest breakthroughs in the field including AlphaStar, AlphaCode, Inception, Minerva, GPT-3.5, and GPT-4. Learn more at https://x.ai/ Read the original press release here.
          Visit Website →

          This will close in 0 seconds

          Mutuo Health Solutions

          Mutuo Health Solutions is a Toronto-based medical artificial intelligence company focused on developing predictive clinical AI technology. Their flagship product, AutoScribe, is an advanced AI-powered ambient scribe solution that transcribes clinician-patient interactions into high-quality electronic medical records in real time. AutoScribe utilizes natural language processing and machine learning technology to accurately capture and structure patient data, enabling healthcare providers to focus on patient care and improve clinical efficiency.

          Visit Website →

          This will close in 0 seconds

          Abstractive Health

          Abstractive Health is on a mission to transform the healthcare industry by automating clinical documentation with generative AI. Their innovative AI software creates comprehensive patient summaries, streamlining workflows and empowering healthcare providers to focus on patient care. By harnessing advanced language models, the company delivers accurate, medically relevant insights directly to clinicians, enabling informed decision-making and improved patient outcomes. Read the original press release here. 

          Visit Website →

          This will close in 0 seconds